In this work, bispecific antibodies were used with the intention to redirect T cells to tumor endothelium in order to mediate T cell activation via CD3 engagement in situ and simultaneously deliver anti-angiogenic effects through T cell cytotoxicity and antibody-mediated blockade of VEGFA binding to VEGFR2 [13,49]. The gene discussed is KDR; the disease is neoplasm.